Home > Resources > Pathogenesis of HIV

Pathogenesis of HIV

Step 1: Not registered? Please complete this form to view content

Step 2: Create Your Medical Product Guide Account

Step 3: Create Your Professional Information

* indicates required field

By clicking the button above you agree to our Terms of Use. We take your privacy seriously. For more information please read our Privacy Policy.

CME Program from The Doctor's Channel

FREE CME

TARGET AUDIENCE
The intended audience for this series is cardiologists, endocrinologists, lipidologists, infectious disease specialists, and other healthcare professionals involved in the diagnosis and treatment of patients with HIV-associated lipodystrophy.

LEARNING OBJECTIVES
At the conclusion of this series, participants should be able to:
?  Review the evidence about the pathogenesis of HIV-associated lipodystrophy, including pathogenic influences associated with host, disease, and treatment-related factors.
?  Diagnose HIV-associated lipodystrophy promptly to improve the overall quality of life in patients with HIV.
?  Use a multidisciplinary approach to assess the effects of HIV disease and HAART therapeutic regimens on the metabolic components of lipodystrophy and monitor for metabolic complications on a regular basis.
?  Evaluate treatments for HIV-associated lipodystrophy based on their safety, efficacy, dosage requirements, and improvement in patients' overall quality of life.
?  Review the etiology, pathophysiology, and impact on cardiovascular risk of the complex dyslipidemias associated with HIV lipodystrophy.
?  Review the evidence concerning the efficacy, safety, drug interactions, and appropriate treatment of the dyslipidemias associated with HIV lipodystrophy to reduce cardiovascular risk.

OVERVIEW
Clinicians who manage patients with HIV must be aware of how to screen for, diagnose, and treat metabolic abnormalities and body shape changes. These video interviews will review the pathophysiology of lipoatrophy and lipohypertrophy, common body shape abnormalities observed in patients with HIV. Methods utilized to detect these body shape changes along with challenges associated with their use will also be discussed. Finally, management strategies for these metabolic and body shape abnormalities will be evaluated.

COURSE CHAIR
Julian Falutz, MD, FRCPC Director, HIV Metabolic Clinic Senior Physician, Division of Geriatrics McGill University Hospital Center Montreal, Quebec